Appili Therapeutics Announces Proposed Non-Brokered Private Placement

Core Viewpoint - Appili Therapeutics Inc. is conducting a non-brokered private placement to raise up to approximately C$750,000 through the issuance of up to 30,000,000 units at a price of $0.025 per unit [1][3]. Group 1: Private Placement Details - Each unit consists of one Class A common share and one-half of a common share purchase warrant, with the whole warrant allowing the purchase of one common share at C$0.05 for 36 months from the closing date [2]. - The private placement is subject to shareholder approval for the warrants and is expected to close in November 2025 [3][4]. - Finders will receive an 8.0% cash fee on gross proceeds and broker warrants equal to 8.0% of the units issued, with similar approval requirements for the broker warrants [4]. Group 2: Use of Proceeds - The net proceeds from the private placement will primarily be used for working capital and to fund the development of certain product candidates [3]. Group 3: Company Overview - Appili Therapeutics is focused on drug development for infectious diseases and biodefense, aiming to address urgent infections with unmet needs [6]. - The company is advancing a diverse range of anti-infectives, including an FDA-approved treatment for antimicrobial resistant infections and a vaccine candidate for tularemia [6].